ES2840454T3 - Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos - Google Patents
Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos Download PDFInfo
- Publication number
- ES2840454T3 ES2840454T3 ES19151824T ES19151824T ES2840454T3 ES 2840454 T3 ES2840454 T3 ES 2840454T3 ES 19151824 T ES19151824 T ES 19151824T ES 19151824 T ES19151824 T ES 19151824T ES 2840454 T3 ES2840454 T3 ES 2840454T3
- Authority
- ES
- Spain
- Prior art keywords
- mmol
- stirred
- concentrated
- mixture
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1CCOCC1 Chemical compound *C1CCOCC1 0.000 description 5
- WRDSDCYKWVXMRY-UHFFFAOYSA-N Brc1c[n](C2CCOCC2)nc1 Chemical compound Brc1c[n](C2CCOCC2)nc1 WRDSDCYKWVXMRY-UHFFFAOYSA-N 0.000 description 1
- KMGKBGKIVPXGBN-UHFFFAOYSA-N CC(c(cc1)c[n]2c1ncc2)N Chemical compound CC(c(cc1)c[n]2c1ncc2)N KMGKBGKIVPXGBN-UHFFFAOYSA-N 0.000 description 1
- BOOVIFJKQGYEON-UHFFFAOYSA-N CC1(C)OB(c2c[n](C3CCOCC3)nc2)OC1(C)C Chemical compound CC1(C)OB(c2c[n](C3CCOCC3)nc2)OC1(C)C BOOVIFJKQGYEON-UHFFFAOYSA-N 0.000 description 1
- YWRBLSYOLXMZGA-UHFFFAOYSA-N CC1(C)OB(c2c[n](CCOC3OCCCC3)nc2)OC1(C)C Chemical compound CC1(C)OB(c2c[n](CCOC3OCCCC3)nc2)OC1(C)C YWRBLSYOLXMZGA-UHFFFAOYSA-N 0.000 description 1
- RKXJJYAAUINCKC-UHFFFAOYSA-P CCOCc1cnc2[n]1cc(CN(c1nc(C(C=[NH2+])=CNC)cnc1[NH3+])N)cc2 Chemical compound CCOCc1cnc2[n]1cc(CN(c1nc(C(C=[NH2+])=CNC)cnc1[NH3+])N)cc2 RKXJJYAAUINCKC-UHFFFAOYSA-P 0.000 description 1
- NVAKRNQHFGHTTQ-VDXUVENESA-O CN/C=C(\C=[NH2+])/c1cnc2NNN(Cc(cc3)c[n]4c3ncc4CO)c2n1 Chemical compound CN/C=C(\C=[NH2+])/c1cnc2NNN(Cc(cc3)c[n]4c3ncc4CO)c2n1 NVAKRNQHFGHTTQ-VDXUVENESA-O 0.000 description 1
- XVRCRQLZQUISKP-UHFFFAOYSA-N CNCc1cnc2[n]1cc(C[n]1nnc(nc3)c1nc3-c1c[n](C)nc1)cc2 Chemical compound CNCc1cnc2[n]1cc(C[n]1nnc(nc3)c1nc3-c1c[n](C)nc1)cc2 XVRCRQLZQUISKP-UHFFFAOYSA-N 0.000 description 1
- DNJVNIZOILDOCW-UHFFFAOYSA-N C[n]1ncc(-c(nc2N(Cc(cc3)c[n]4c3ncc4)N)cnc2N)c1 Chemical compound C[n]1ncc(-c(nc2N(Cc(cc3)c[n]4c3ncc4)N)cnc2N)c1 DNJVNIZOILDOCW-UHFFFAOYSA-N 0.000 description 1
- HWQZQGUNPZBXNP-UHFFFAOYSA-N C[n]1ncc(-c2nc([n](Cc(cc3)c[n]4c3ncc4)nn3)c3nc2)c1 Chemical compound C[n]1ncc(-c2nc([n](Cc(cc3)c[n]4c3ncc4)nn3)c3nc2)c1 HWQZQGUNPZBXNP-UHFFFAOYSA-N 0.000 description 1
- SJLIQCLYTBENCZ-UHFFFAOYSA-N Clc(cc1)nc2c1nn[n]2Cc1nc2cnccc2[s]1 Chemical compound Clc(cc1)nc2c1nn[n]2Cc1nc2cnccc2[s]1 SJLIQCLYTBENCZ-UHFFFAOYSA-N 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N OC1CCOCC1 Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- BAXYSPKYZYFGMF-UHFFFAOYSA-N OCC[n]1ncc(-c(cc2)nc3c2nn[n]3Cc2nc3cnccc3[s]2)c1 Chemical compound OCC[n]1ncc(-c(cc2)nc3c2nn[n]3Cc2nc3cnccc3[s]2)c1 BAXYSPKYZYFGMF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009076321 | 2009-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2840454T3 true ES2840454T3 (es) | 2021-07-06 |
Family
ID=44226181
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19151824T Active ES2840454T3 (es) | 2009-12-31 | 2010-12-30 | Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos |
| ES13198224.1T Active ES2546635T3 (es) | 2009-12-31 | 2010-12-30 | Ciertas triazolopirazinas, composiciones de éstas y sus métodos de empleo |
| ES20199091T Active ES2927146T3 (es) | 2009-12-31 | 2010-12-30 | Ciertas triazolopirazinas, composiciones de estas y sus métodos de empleo |
| ES15170608T Active ES2726152T3 (es) | 2009-12-31 | 2010-12-30 | Ciertas triazolopiridinas, composiciones de estas y su uso en el tratamiento del cáncer |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13198224.1T Active ES2546635T3 (es) | 2009-12-31 | 2010-12-30 | Ciertas triazolopirazinas, composiciones de éstas y sus métodos de empleo |
| ES20199091T Active ES2927146T3 (es) | 2009-12-31 | 2010-12-30 | Ciertas triazolopirazinas, composiciones de estas y sus métodos de empleo |
| ES15170608T Active ES2726152T3 (es) | 2009-12-31 | 2010-12-30 | Ciertas triazolopiridinas, composiciones de estas y su uso en el tratamiento del cáncer |
Country Status (38)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2719699B1 (en) | 2009-12-31 | 2015-07-08 | Hutchison Medipharma Limited | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| CA2798080C (en) | 2010-05-17 | 2020-08-25 | Incozen Therapeutics Pvt. Ltd. | 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
| CN102516046A (zh) * | 2011-11-22 | 2012-06-27 | 太仓市运通化工厂 | 一种2-溴丙醛的合成方法 |
| AP3908A (en) * | 2012-03-30 | 2016-11-24 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases |
| CA2776178A1 (en) | 2012-04-05 | 2013-10-05 | Hydro-Quebec | Ionic compounds |
| KR101745741B1 (ko) | 2012-08-13 | 2017-06-12 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
| WO2014109414A1 (ja) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
| MY186126A (en) | 2013-03-06 | 2021-06-24 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
| CN103265468A (zh) * | 2013-06-17 | 2013-08-28 | 连云港盛和生物科技有限公司 | 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法 |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| JP6039095B2 (ja) * | 2013-09-30 | 2016-12-07 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 新規なトリアゾロピラジン誘導体及びその用途 |
| SI3087070T1 (en) * | 2013-12-26 | 2018-01-31 | Ignyta, Inc. | Pyrazolo (1,5-a) pyridine derivatives and processes for their use |
| JP2016048495A (ja) * | 2014-08-28 | 2016-04-07 | 京セラ株式会社 | 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法 |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| CN109369657B (zh) * | 2015-12-31 | 2021-05-07 | 上海医药集团股份有限公司 | 喹啉类化合物柠檬酸盐的晶型、制备方法、组合物与应用 |
| GB201616116D0 (en) | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| KR20180092096A (ko) | 2017-02-08 | 2018-08-17 | 에이비온 주식회사 | 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| DK3985002T3 (da) | 2017-03-01 | 2025-08-18 | Achillion Pharmaceuticals Inc | Farmaceutiske aryl-, heteroaryl- og heterocyclylforbindelser til behandling af medicinske forstyrrelser |
| CN108570053A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元并六元杂环化合物、制备方法、中间体、组合和应用 |
| KR101924801B1 (ko) | 2017-08-16 | 2018-12-04 | 한국원자력의학원 | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| BR112021004263A2 (pt) | 2018-09-06 | 2021-05-25 | Achillion Pharmaceuticals, Inc. | formas mórficas de danicopano |
| JP7629402B2 (ja) | 2018-09-11 | 2025-02-13 | アストラゼネカ・アクチエボラーグ | ３－［（１Ｓ）－１－イミダゾ［１，２－ａ］ピリジン－６－イルエチル］－５－（１－メチルピラゾール－４－イル）トリアゾロ［４，５－ｂ］ピラジン及びその多形相の改良製造法 |
| KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
| BR112021008336A2 (pt) | 2018-10-30 | 2021-08-03 | Repare Therapeutics Inc. | compostos, composições farmacêuticas, e métodos de preparação de compostos e de seu uso como inibidores de atr quinase |
| AU2019395282A1 (en) | 2018-12-14 | 2021-07-08 | Beta Pharma, Inc. | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof |
| JP7471300B2 (ja) | 2018-12-17 | 2024-04-19 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体介在性疾患を治療するための的を絞った投与 |
| KR20220004024A (ko) | 2019-03-22 | 2022-01-11 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 약제학적 조성물 |
| AU2020317381A1 (en) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc. | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors |
| JP2023515073A (ja) * | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| WO2021229605A1 (en) * | 2020-05-14 | 2021-11-18 | Dr. Reddy's Laboratories Limited | Process for preparation of savolitinib and its intermediates |
| CA3193755A1 (en) * | 2020-09-28 | 2022-03-31 | Codexis, Inc. | Engineered biocatalysts and methods for synthesizing chiral amines |
| WO2022133046A2 (en) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR102659095B1 (ko) | 2021-01-08 | 2024-04-19 | 에이비온 주식회사 | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 |
| CN113278019A (zh) * | 2021-05-31 | 2021-08-20 | 河南偶联生物科技有限公司 | 一种咪唑并[1,2-a]吡啶类化合物的合成方法 |
| EP4511025A1 (en) * | 2022-04-20 | 2025-02-26 | Engrail Therapeutics, Inc. | GABAa RECEPTOR MODULATOR SALTS, PARTICLES, AND USES THEREOF |
| IL318241A (en) | 2022-07-08 | 2025-03-01 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment |
| CN119998281A (zh) * | 2022-07-29 | 2025-05-13 | 贝勒医学院 | 神经营养受体酪氨酸激酶(ntrk)抑制剂及其使用方法 |
| CN115611802B (zh) * | 2022-12-02 | 2023-03-14 | 北京迪泰医药科技有限公司 | 一种3-乙酰基-2-氯吡啶的合成方法 |
| CN120835885A (zh) * | 2023-01-04 | 2025-10-24 | 缆图药品公司 | Cdk2抑制剂 |
| GB202300923D0 (en) * | 2023-01-20 | 2023-03-08 | Macfarlan Smith Ltd | Novel polymorphic forms of savolitinib |
| WO2024263860A1 (en) * | 2023-06-22 | 2024-12-26 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1999061442A1 (en) * | 1998-05-26 | 1999-12-02 | Merck & Co., Inc. | Imidazopyridine thrombin inhibitors |
| JP2000119250A (ja) * | 1998-08-11 | 2000-04-25 | Takeda Chem Ind Ltd | 環状アミド化合物、その製造法、中間体及び除草剤 |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| CA2530589A1 (en) * | 2003-07-02 | 2005-01-20 | Sugen Inc. | Arylmethyl triazolo and imidazopyrazines as c-met inhibitors |
| JP2007504243A (ja) | 2003-09-03 | 2007-03-01 | ニューロジェン・コーポレーション | ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物 |
| EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| CA2577478A1 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| SI1853602T1 (sl) * | 2005-02-16 | 2010-11-30 | Astrazeneca Ab | Kemične spojine |
| AU2006320580B2 (en) | 2005-11-30 | 2011-06-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| EP1966214B9 (en) * | 2005-12-21 | 2017-09-13 | Janssen Pharmaceutica N.V. | Triazolopyridazines as tyrosine kinase modulators |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| JP2009538899A (ja) * | 2006-05-30 | 2009-11-12 | ファイザー・プロダクツ・インク | トリアゾロピリダジン誘導体 |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| TW200817410A (en) | 2006-08-07 | 2008-04-16 | Incyte Corp | Triazolotriazines as kinase inhibitors |
| JP2010519174A (ja) | 2006-09-18 | 2010-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−Ｍｅｔの複素環阻害薬およびその使用方法 |
| DK2084162T3 (da) | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Bicykliske triazoler som proteinkinasemodulatorer |
| DK2081937T3 (da) * | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Triazolopyridazin-proteinkinasemodulatorer |
| EP2497470B8 (en) | 2006-11-22 | 2015-12-02 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| JP2010524858A (ja) | 2007-04-10 | 2010-07-22 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 縮合環複素環キナーゼ調節因子 |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| US8673970B2 (en) * | 2008-02-21 | 2014-03-18 | Sequoia Pharmaceuticals, Inc. | HIV protease inhibitor and cytochrome p450 inhibitor combinations |
| JP5576802B2 (ja) | 2008-02-28 | 2014-08-20 | ノバルティス アーゲー | Ｃ−Ｍｅｔチロシンキナーゼ介在疾患の治療用のイミダゾ［１，２−ｂ］ピリダジン誘導体 |
| MX2010012528A (es) | 2008-05-22 | 2010-12-02 | Amgen Inc | Heterociclos como inhibidores de proteina cinasa. |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| KR20120089643A (ko) * | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
| JP5775871B2 (ja) * | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| EP2719699B1 (en) | 2009-12-31 | 2015-07-08 | Hutchison Medipharma Limited | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| CA2798080C (en) | 2010-05-17 | 2020-08-25 | Incozen Therapeutics Pvt. Ltd. | 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
-
2010
- 2010-12-30 EP EP13198224.1A patent/EP2719699B1/en active Active
- 2010-12-30 PE PE2020001800A patent/PE20211094A1/es unknown
- 2010-12-30 PL PL13198224T patent/PL2719699T3/pl unknown
- 2010-12-30 SG SG2012044830A patent/SG181781A1/en unknown
- 2010-12-30 RS RS20201567A patent/RS61281B1/sr unknown
- 2010-12-30 ME MEP-2015-150A patent/ME02211B/me unknown
- 2010-12-30 US US13/501,222 patent/US8987269B2/en active Active
- 2010-12-30 PL PL20199091.8T patent/PL3795573T3/pl unknown
- 2010-12-30 DK DK13198224.1T patent/DK2719699T3/en active
- 2010-12-30 HU HUE20199091A patent/HUE059696T2/hu unknown
- 2010-12-30 MX MX2012007756A patent/MX336996B/es active IP Right Grant
- 2010-12-30 DK DK19151824.0T patent/DK3511330T3/da active
- 2010-12-30 BR BR112012016129-6A patent/BR112012016129B1/pt active IP Right Grant
- 2010-12-30 ES ES19151824T patent/ES2840454T3/es active Active
- 2010-12-30 CA CA2785749A patent/CA2785749C/en active Active
- 2010-12-30 JP JP2012546344A patent/JP5337313B2/ja active Active
- 2010-12-30 WO PCT/CN2010/080499 patent/WO2011079804A1/en not_active Ceased
- 2010-12-30 HU HUE19151824A patent/HUE052828T2/hu unknown
- 2010-12-30 KR KR1020147010967A patent/KR101771299B1/ko active Active
- 2010-12-30 HU HUE13198224A patent/HUE025504T2/en unknown
- 2010-12-30 PT PT131982241T patent/PT2719699E/pt unknown
- 2010-12-30 PT PT201990918T patent/PT3795573T/pt unknown
- 2010-12-30 ES ES13198224.1T patent/ES2546635T3/es active Active
- 2010-12-30 HR HRP20221090TT patent/HRP20221090T1/hr unknown
- 2010-12-30 CN CN201080065014.1A patent/CN102906092B/zh active Active
- 2010-12-30 PL PL19151824T patent/PL3511330T3/pl unknown
- 2010-12-30 DK DK20199091.8T patent/DK3795573T3/da active
- 2010-12-30 EA EA201691461A patent/EA030141B1/ru not_active IP Right Cessation
- 2010-12-30 CN CN201610437304.3A patent/CN106117248B/zh active Active
- 2010-12-30 PT PT191518240T patent/PT3511330T/pt unknown
- 2010-12-30 EP EP15170608.2A patent/EP2966075B1/en active Active
- 2010-12-30 EP EP10840591.1A patent/EP2519524A4/en not_active Withdrawn
- 2010-12-30 KR KR1020177022937A patent/KR101905350B1/ko active Active
- 2010-12-30 RS RS20150584A patent/RS54217B1/sr unknown
- 2010-12-30 SM SM20220371T patent/SMT202200371T1/it unknown
- 2010-12-30 EP EP20199091.8A patent/EP3795573B1/en active Active
- 2010-12-30 EA EA201200951A patent/EA025466B1/ru not_active IP Right Cessation
- 2010-12-30 PH PH1/2012/501355A patent/PH12012501355A1/en unknown
- 2010-12-30 ES ES20199091T patent/ES2927146T3/es active Active
- 2010-12-30 SI SI201031021T patent/SI2719699T1/sl unknown
- 2010-12-30 CN CN201610432059.7A patent/CN106432225B/zh active Active
- 2010-12-30 AU AU2010338712A patent/AU2010338712B2/en active Active
- 2010-12-30 NZ NZ601128A patent/NZ601128A/en unknown
- 2010-12-30 PE PE2016000292A patent/PE20160588A1/es unknown
- 2010-12-30 CU CU20120101A patent/CU24167B1/es active IP Right Grant
- 2010-12-30 UA UAA201208929A patent/UA107822C2/ru unknown
- 2010-12-30 PE PE2012000903A patent/PE20130375A1/es not_active Application Discontinuation
- 2010-12-30 SM SM20200693T patent/SMT202000693T1/it unknown
- 2010-12-30 KR KR1020127019509A patent/KR101434766B1/ko active Active
- 2010-12-30 LT LTEP20199091.8T patent/LT3795573T/lt unknown
- 2010-12-30 SI SI201032046T patent/SI3511330T1/sl unknown
- 2010-12-30 RS RS20220854A patent/RS63612B1/sr unknown
- 2010-12-30 MX MX2016001733A patent/MX386852B/es unknown
- 2010-12-30 ES ES15170608T patent/ES2726152T3/es active Active
- 2010-12-30 EP EP19151824.0A patent/EP3511330B1/en active Active
- 2010-12-30 MY MYPI2012002974A patent/MY179933A/en unknown
-
2012
- 2012-04-10 US US13/501,224 patent/US8507487B2/en active Active
- 2012-06-14 IL IL220433A patent/IL220433B/en active IP Right Grant
- 2012-06-26 CL CL2012001752A patent/CL2012001752A1/es unknown
- 2012-06-28 GT GT201200220A patent/GT201200220A/es unknown
- 2012-06-29 EC EC2012012011A patent/ECSP12012011A/es unknown
- 2012-06-29 DO DO2012000188A patent/DOP2012000188A/es unknown
- 2012-06-29 NI NI201200118A patent/NI201200118A/es unknown
- 2012-06-29 CO CO12109937A patent/CO6612235A2/es not_active Application Discontinuation
- 2012-07-30 ZA ZA2012/05730A patent/ZA201205730B/en unknown
-
2013
- 2013-06-11 JP JP2013122502A patent/JP2013209418A/ja active Pending
-
2015
- 2015-01-21 US US14/601,674 patent/US20150368271A1/en not_active Abandoned
- 2015-06-23 AU AU2015203480A patent/AU2015203480B2/en active Active
- 2015-07-16 IL IL239997A patent/IL239997A/en active IP Right Grant
- 2015-09-08 HR HRP20150952TT patent/HRP20150952T1/hr unknown
- 2015-09-09 SM SM201500213T patent/SMT201500213B/xx unknown
- 2015-09-17 CY CY20151100816T patent/CY1118250T1/el unknown
-
2016
- 2016-04-04 JP JP2016074893A patent/JP6194046B2/ja active Active
- 2016-10-14 US US15/293,722 patent/US9956218B2/en active Active
-
2017
- 2017-08-10 JP JP2017155493A patent/JP6486999B2/ja active Active
-
2018
- 2018-04-04 US US15/945,324 patent/US10512645B2/en active Active
-
2019
- 2019-02-20 JP JP2019028197A patent/JP6647434B2/ja active Active
- 2019-11-08 US US16/678,091 patent/US10946014B2/en active Active
-
2020
- 2020-12-17 HR HRP20202017TT patent/HRP20202017T1/hr unknown
- 2020-12-21 CY CY20201101206T patent/CY1123777T1/el unknown
-
2021
- 2021-02-03 US US17/248,688 patent/US11896592B2/en active Active
-
2023
- 2023-12-13 US US18/538,151 patent/US20240139182A1/en not_active Abandoned
-
2024
- 2024-05-28 US US18/676,172 patent/US20250099462A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2840454T3 (es) | Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos | |
| HK40049874A (en) | Certain triazolopyrazines, compositions thereof and methods of use therefor | |
| HK40049874B (en) | Certain triazolopyrazines, compositions thereof and methods of use therefor | |
| HK40011539A (en) | Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors | |
| HK40011539B (en) | Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors | |
| HK1216880B (en) | Certain triazolopyridines, compositions thereof and their use in the treatment of cancer. |